Loading
Developed the first antibody treatment for cancer, rituximab, and still works on training the immune system against lymphoma.
Ronald Levy is Robert K. and Helen K. Summy Professor of Medicine (Oncology) at Stanford University, within the Stanford Cancer Institute. An oncologist specialising in lymphoma and antibody therapy, his anti-idiotype and anti-CD20 antibody work led to rituximab, the first approved cancer antibody. His papers include the New England Journal of Medicine report on treatment of B-cell lymphoma with monoclonal anti-idiotype antibody and a Science Translational Medicine study on eradication of spontaneous malignancy by local immunotherapy. His current work tests in situ vaccination with TLR agonists and anti-OX40 in low-grade lymphoma, linking monoclonal antibodies, CD20 and innate immune agonists to diffuse large B-cell lymphoma.
| Title | Journal | Year |
|---|---|---|
| Eradication of spontaneous malignancy by local immunotherapy | Science Translational Medicine | 2018 |
| Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody | New England Journal of Medicine | 1982 |
Shares CD20, Diffuse large B-cell lymphoma.
Shares CD20, Diffuse large B-cell lymphoma.
Shares Stanford Health Care / Stanford Cancer Institute, Monoclonal antibodies.
Shares CD20, Diffuse large B-cell lymphoma.
Shares CD20, Diffuse large B-cell lymphoma.
Shares CD20, Diffuse large B-cell lymphoma.
Shares CD20, Diffuse large B-cell lymphoma.
Shares Stanford Health Care / Stanford Cancer Institute, Diffuse large B-cell lymphoma.